S&P 500   3,852.36
DOW   32,920.46
QQQ   303.47
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Biden Likely HATES This Video (Ad)
What do Mastercard Earnings Indicate About Consumer Spending?
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
Adani woes spur protests as stock turmoil turns political
Route to Super Bowl dangerous for Mexico's avocado haulers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Biden's State of the Union to tout policy wins on economy
Evacuations urged in Ohio town as train wreck smolders
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.47
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Biden Likely HATES This Video (Ad)
What do Mastercard Earnings Indicate About Consumer Spending?
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
Adani woes spur protests as stock turmoil turns political
Route to Super Bowl dangerous for Mexico's avocado haulers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Biden's State of the Union to tout policy wins on economy
Evacuations urged in Ohio town as train wreck smolders
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.47
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Biden Likely HATES This Video (Ad)
What do Mastercard Earnings Indicate About Consumer Spending?
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
Adani woes spur protests as stock turmoil turns political
Route to Super Bowl dangerous for Mexico's avocado haulers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Biden's State of the Union to tout policy wins on economy
Evacuations urged in Ohio town as train wreck smolders
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.47
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Biden Likely HATES This Video (Ad)
What do Mastercard Earnings Indicate About Consumer Spending?
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
Adani woes spur protests as stock turmoil turns political
Route to Super Bowl dangerous for Mexico's avocado haulers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Biden's State of the Union to tout policy wins on economy
Evacuations urged in Ohio town as train wreck smolders
NASDAQ:ACAD

ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News

$19.83
-0.08 (-0.40%)
(As of 02/3/2023 09:03 PM ET)
Add
Compare
Today's Range
$19.53
$20.11
50-Day Range
$14.49
$19.91
52-Week Range
$12.24
$28.06
Volume
1.23 million shs
Average Volume
1.25 million shs
Market Capitalization
$3.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.56

ACADIA Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3.7% Upside
$20.56 Price Target
Short Interest
Bearish
5.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$342,038 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.31) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

854th out of 1,025 stocks

Pharmaceutical Preparations Industry

418th out of 498 stocks

ACAD stock logo

About ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Analyst Expectations for ACADIA Pharmaceuticals's Future
Acadia Pharmaceuticals: What's Ahead In 2023
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
U.S. FDA approves Roche's lymphoma therapy
U.S. FDA approves Roche's COVID-19 antibody
RBC Capital Keeps Their Buy Rating on Spruce Biosciences (SPRB)
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Company Calendar

Last Earnings
11/08/2021
Today
2/06/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
514
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.56
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+3.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
18 Analysts

Profitability

Net Income
$-167,870,000.00
Pretax Margin
-42.12%

Debt

Sales & Book Value

Annual Sales
$484.14 million
Book Value
$3.36 per share

Miscellaneous

Free Float
115,943,000
Market Cap
$3.21 billion
Optionable
Optionable
Beta
0.64

Key Executives

  • Stephen R. DavisStephen R. Davis
    Chief Executive Officer & Director
  • Brendan P. TeehanBrendan P. Teehan
    Chief Operating Officer, EVP & Head-Commercial
  • Mark C. Schneyer
    Chief Financial Officer & Executive Vice President
  • Bob Mischler
    Senior VP-Strategy & Technology Operations
  • Ponni Subbiah
    Chief Medical Officer & Senior Vice President













ACAD Stock - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACAD shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price forecast for 2023?

18 brokers have issued twelve-month price objectives for ACADIA Pharmaceuticals' shares. Their ACAD share price forecasts range from $10.00 to $35.00. On average, they anticipate the company's share price to reach $20.56 in the next year. This suggests a possible upside of 3.7% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2023?

ACADIA Pharmaceuticals' stock was trading at $15.92 at the start of the year. Since then, ACAD shares have increased by 24.6% and is now trading at $19.83.
View the best growth stocks for 2023 here
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.17. The biopharmaceutical company had revenue of $131.61 million for the quarter, compared to analysts' expectations of $127.77 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 47.09% and a negative net margin of 42.49%. The company's quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.54) EPS.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $510.00 million-$520.00 million, compared to the consensus revenue estimate of $530.69 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (0.82%), Emerald Mutual Fund Advisers Trust (0.65%), Rice Hall James & Associates LLC (0.59%), Hennion & Walsh Asset Management Inc. (0.13%), Empire Life Investments Inc. (0.11%) and State of New Jersey Common Pension Fund D (0.10%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, James M Daly, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $19.83.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.21 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167,870,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

The company employs 514 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 2/6/2023 by MarketBeat.com Staff